[{"id":"6fe8f0e9-8178-43af-8474-eda668b88de5","acronym":"MULAN","url":"https://clinicaltrials.gov/study/NCT04355858","created_at":"2021-01-18T21:03:24.371Z","updated_at":"2024-07-02T16:36:06.637Z","phase":"Phase 2","brief_title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","source_id_and_acronym":"NCT04355858 - MULAN","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR7390 • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 319","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-07-26"}]